Shots:

• The FDA’s fast track designation is based on P-III DAPA-CKD study assessing Farxiga (dapagliflozin) vs PBO on renal outcomes and CV mortality in patients with CKD with and without T2D- on the top of SOC
• The FDA’s Fast Track designation is designed to accelerate the development and review of new therapies for the treatment of serious conditions where there is an unmet medical need
• Farxiga (qd) is an oral SGLT2 inhibitor indicated both as a monothx. and combination therapy to improve glycemic control- with weight loss and reduction in BP- as an adjunct to diet and exercise in adults with T2D

Click here to­ read full press release/ article

Ref: Abbott | Image: AstraZeneca